Back to search results

Study of Suzetrigine and Efavirenz in Healthy Volunteers

This study is looking at how two medicines, Suzetrigine and Efavirenz, interact in the body. Suzetrigine is being studied for pain. Efavirenz is a medicine that can affect how other drugs are processed. Researchers want to understand how Efavirenz changes the levels of Suzetrigine and its breakdown product in your blood, and to check if taking them together is safe. You might be able to join if you are a healthy adult between 18 and 55 years old, weigh more than 50 kg, and have a BMI between 18 and 32. The study will measure the highest amount of Suzetrigine in your blood and how much is in your blood over time. The study aims to enroll 18 participants, but its current recruitment status is unclear.

Study design
This interventional study is designed to evaluate drug interactions in healthy participants. It will involve 18 participants.
What's involved
You would receive study medication for 30 days. The study includes a screening phase, a treatment phase, and a safety follow-up phase.
Compensation
Not stated in the trial record.
Follow-up
Participants will have a safety follow-up phase after the 30-day treatment period, with measurements taken at Day 15 and Day 30.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07570069

Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants

Completed
PHASE1Ages 18–55InterventionalTreatment
Vertex Pharmaceuticals Incorporated
~18 participants
Updated 2026-08-18 on ClinicalTrials.gov
What's tested:SuzetrigineEfavirenz

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum Observed Plasma Concentration (Cmax) of SUZ and its Metabolite in the Absence and Presence of Efavirenz
Measured over Day 15 and Day 30
+1 more outcome measured

Conditions

Pain

Explore related trials

Healthy Volunteers

NCT07570069

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • ICON - Utah - Salt Lake City Office

    Salt Lake City, Utahno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
A total body weight of greater than (\>) 50 kg
Males and females of non-childbearing potential

Exclusion

History of any illness or any clinical condition that may confound the results of the study or pose an additional risk in administering study drug to the participant
History of febrile illness or other acute illness that has not fully resolved within 5 days before the first dose of study drug
Any condition possibly affecting drug absorption

What this trial measures

  • Maximum Observed Plasma Concentration (Cmax) of SUZ and its Metabolite in the Absence and Presence of EfavirenzDay 15 and Day 30
  • Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCτ) of SUZ and its Metabolite in the Absence and Presence of EfavirenzDay 15 and Day 30